Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Impedimed Limited ( (AU:IPD) ) has shared an update.
ImpediMed Limited announced that it will release its quarterly cash flow report for the period ending March 31, 2025, on April 30, 2025. The company will host an investor conference call on the same day, led by CEO Dr. Parmjot Bains and CF&OO McGregor Grant, providing stakeholders an opportunity to engage with management and discuss the company’s financial performance and outlook.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on non-invasive medical devices for the assessment of fluid status and body composition. The company is known for its products that aid in the management of lymphedema, heart failure, and other conditions requiring fluid monitoring.
YTD Price Performance: -50.0%
Average Trading Volume: 78,225
Technical Sentiment Signal: Buy
Current Market Cap: $47.59M
Learn more about IPD stock on TipRanks’ Stock Analysis page.